Skip to main content

APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19

Written by Petra Hegmann on . Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]